Baiyunshan (00874.HK): Zhongyi Pharmaceutical has received the "Approval Notice for Clinical Trial of Drug" for the new therapeutic function of the eye-caring tablets.

According to the Zhitong Finance APP, Baiyunshan (00874.HK) announced that recently, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") subsidiary Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhongyi Pharmaceutical") received the "Approval Notice for Drug Clinical Trials" issued by the National Medical Products Administration, which approves the new therapeutic function of the eye-treatment tablets.